* If you want to update the article please login/register
Patients with a TBSA burn > 30 percent will be accepted and followed for 90 days after admission. Secondary Objectives Describe the prognosis of patients with significant burns, with a special emphasis on the effects of albumin on patient prognosis in patients with severe burns.
Source link: https://clinicaltrials.gov/ct2/show/NCT04264065
OBJECTIVES: Primary Objective: Determine age-related changes in the pharmacokinetics of a weekly paclitaxel-stabilized nanoparticle formulation in patients with metastatic breast cancer patients. In these patients, it is difficult to determine age-related changes in the pharmacokinetics of nab-paclitaxel. In these patients, we wanted to find predictors of pK values. Patients are provided with paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes every day on days 1, 8, and 15, as intended. During course 1, Blood is drawn for pharmacokinetic tests regularly. Patients complete questionnaires on risk factors that could predict for pharmacokinetic parameters at baseline, prior to the third course of study, and at the end of the research.
Source link: https://clinicaltrials.gov/ct2/show/NCT00609791
The investigation will use 3H-cholesterol bound to albumin to determine how HDL can move cholesterol from the periphery to the liver in order to be eliminated. This process is known as reverse cholesterol transport, and it is one of the primary ways that HDL guards against atherosclerotic cardiovascular disease. Validating RCT results is critical for the development of new drugs that affect RCT and may lead to helpful treatments for atherosclerosis.
Source link: https://clinicaltrials.gov/ct2/show/NCT01782027
Patients with severe POTS also responded positively to weekly albumin therapy, supporting the investigator's assertion that periodic albumin infusions would provide significant and sustained symptomatic relief to patients with chronic POTS. Exercise Testing: The change in maximal exercise capacity of the patients from baseline using peak oxygen consumption varies. During the two-year research period, fifteen patients with severe neuropathic condition primary POTS will be recruited from the University of Alberta Hospital Autonomic Clinic. The percentage change of tachycardia from baseline on tilt table test results within three days of completion of each study arm will be determined using validated symptom scales at the end of each study period and the percentage reduction of tachycardia from baseline on tilt table tests performed within three days of completion of each study arm. Subjects will be randomly assigned to one of two treatment arms: one arm will be given 5% albumin in a dose of 1 gm/kg for four weeks, and the other arm will receive the same amount on a volume basis of Saline weekly for four weeks. At the end of the study period, the patients will have a 4-week washout period followed by the opposite treatment arm from the first study period. As part of Mayo Clinic Protocols at baseline, autonomic testing will be performed, as part of orthostatic intolerance, as described in the following tests: i. Quantitative Sudomotor Axon Reflex Test Patients will also undergo detailed autonomic testing will be performed, as per Mayo Clinic Protocols at baseline. Patients will be tilted to a 90 degree angle for ten minutes after being seated back to supine position for another 5 minutes after baseline data of 2-5 minutes. Exercise Tolerance: An exercise physiologist/rehabilitation specialist at baseline and the end of the study will determine the effect of intervention on the participants' physical capabilities. f. Patient Diaries Patients will be required to keep a daily diary of their illnesses using the OSGS and PHAQ-20 scales, as well as sleep diaries during the screening and evaluation periods. Patients will record two-daily blood pressures to determine the risk of any orthostatic hypertension using provided blood pressure monitors. Any potential adverse effects related to albumin infusions that have not been identified by the study participants or infusion nurses will be noted. In the active arm of the study, OSGS results at baseline will not be significantly different at the end of the study's time. Secondary studies will be carried out with a paired t-test comparing the scores on HAQ-20 scales and degree of tachycardia at the same time points. Based on the following observations: Patients start showing symptomatic improvement within a few weeks of albumin infusions, according to preliminary results: The duration of each arm of the study and outcome measures was determined.
Source link: https://clinicaltrials.gov/ct2/show/NCT03365414
Compared to paclitaxel, and with ixabepilone as compared to paclitaxel, we'll investigate the correlation between rises in blood counts of circulating tumor cells and circulating endothelial cells to PFS and secondary endpoints of response during chemotherapy with nab-paclitaxel and paclitaxel. With PFS and secondary endpoints of response during treatment with nab-paclitaxel, compared to paclitaxel, and with ixabepilone as compared to paclitaxel, we can determine the correlation between expression levels of tau and beta-tubulin isotype composition. cytochrome P450, family 3, subfamily A, polypeptide 4, subfamily A, sub-family B, polypeptide 5, sub-family A, sub-family A, sub-family B, subfamily A, ATP-binding cassette, sub-family B, member 1, member 1 and ATP-binding cassette, sub-family C, member 2 polymorphisms with response and toxicity profiles, cytochrome P450, family 3, sub-family A, cytochrome P450, family 3, sub-sub-biom 4 cytochrome 4 cytochrome P450, polypeptide 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 5 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 cytochrome 4 phosphate 4 cytochrome P450, sub-family C cytochrome P450, sub-family A, sub-binder To perform an exploratory analysis of whether other factors in patient assessments influence the risk of grade 3, 4, or 5 toxicity in patients receiving weekly paclitaxel, nab-paclitaxel, or ixabepilone treated with or without bevacizumab, with a particular focus on pre-existing hypertension or neuropathy. Patients can also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Patients are given a paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Bevacizumab can also be administered as in Arm A. Patients in Arm A. may also be vacizumab as a result of disease progression or unacceptable toxicity as of 7/18/11. In all arms, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Source link: https://clinicaltrials.gov/ct2/show/NCT00785291
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions